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82Objective: The aim of the Advanced Approach to Arterial
Stiffness study was to compare arterial stiffness measured
simultaneously with two different methods in different age
groups of middle-aged and older adults with or without
metabolic syndrome (MetS). The specific effects of the
different MetS components on arterial stiffness were also
studied.
Methods: This prospective, multicentre, international
study included 2224 patients aged 40 years and older,
1664 with and 560 without MetS. Patients were enrolled
in 32 centres from 18 European countries affiliated to the
International Society of Vascular Health & Aging. Arterial
stiffness was evaluated using the cardio-ankle vascular
index (CAVI) and the carotid–femoral pulse wave velocity
(CF-PWV) in four prespecified age groups: 40–49, 50–59,
60–74, 75–90 years. In this report, we present the
baseline data of this study.
Results: Both CF-PWV and CAVI increased with age, with
a higher correlation coefficient for CAVI (comparison of
coefficients P< 0.001). Age-adjusted and sex-adjusted
values of CF-PWV and CAVI were weakly intercorrelated
(r2¼0.06, P<0.001). Age-adjusted and sex-adjusted
values for CF-PWV but not CAVI were higher in presence
of MetS (CF-PWV: 9.57 0.06 vs. 8.650.10, P< 0.001;
CAVI: 8.340.03 vs. 8.290.04, P¼0.40; mean SEM;
MetS vs. no MetS). The absence of an overall effect of
MetS on CAVI was related to the heterogeneous effects of
the components of MetS on this parameter: CAVI was
positively associated with the high glycaemia and high
blood pressure components, whereas lacked significant
associations with the HDL and triglycerides components
while exhibiting a negative association with the overweight
component. In contrast, all five MetS components showed
positive associations with CF-PWV.
Conclusion: This large European multicentre study reveals
a differential impact of MetS and age on CAVI and CF-DOI:10.1097/HJH.0000000000001631
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Metabolic syndrome and arterial stiffnessPWV and suggests that age may have a more pronounced
effect on CAVI, whereas MetS increases CF-PWV but not
CAVI. This important finding may be due to
heterogeneous effects of MetS components on CAVI. The
clinical significance of these original results will be assessed
during the longitudinal phase of the study.
Keywords: aging, arterial stiffness, cardio-ankle vascular
index, large artery, metabolic syndrome, pulse wave
velocity
Abbreviations: ABPM, ambulatory blood pressure
monitoring; BP, blood pressure; CAVI, cardio-ankle vascular
index; CF-PWV, carotid–femoral pulse wave velocity; MetS,
metabolic syndrome; NCEP, National Cholesterol Education
Program; PP, pulse pressure; PWV, pulse wave velocityINTRODUCTIONC
hanges in body composition in men and women
occur with aging with exponential loss of lean
tissues [1]. The prevalence of cardiovascular risk
factors and metabolic syndrome (MetS) dramatically
increases with age at least until the age of 60 years [2]. This
is observed in both developed [3] and even more in devel-
oping countries [4]. Therefore, MetS is becoming a pan-
demic disease with major consequences on public health.
The influence of the different metabolic and haemody-
namic components of MetS on arterial health has been
assessed in different clinical studies. A relationship has
been demonstrated between the presence of MetS and
progression of arterial stiffness of the aorta and other large
arteries [5,6]. In a previous longitudinal study, an accelera-
tion of arterial aging over a period of 7 years was shown as a
function of the number of components of the MetS [7]. In
addition, the presence of nonalcoholic fatty liver disease
has also been shown to be associated with increased
pulse wave velocity (PWV) especially when this condition
was associated with MetS [8]. However, it is unknown
whether MetS as a whole and its different components
affect arterial stiffness to the same extent in younger and
elderly individuals.
Carotid–femoral pulse wave velocity (CF-PWV) has
been considered as the ‘gold standard’ [9–12] measurement
of arterial stiffness, due to the large number of studies
identifying PWV as an independent predictor of total mor-
tality and cardiovascular events [13–16]. However, despite
the importance of PWV, this method presents a number of
limitations and sources of inaccuracy. First, the determina-
tion of the transit distance travelled by the pressure waves
using body surface measurements may not reliably repre-
sent the true length of the arterial segment, especially with
obesity and when the arteries become more tortuous
with age. Second, CF-PWV is not a simple unidirectional
path length for the pulse wave; therefore, determination of
the actual travelled path length is somewhat approximate
[11]. Moreover, several confounding factors (physiological
and technical) for PWV have been reported. The
most significant physiological factors affecting PWV are
blood pressure (BP) and heart rate, whereas technicalJournal of Hypertensionconfounders include the algorithm of the used device
and the considered arterial pathway (carotid–femoral, bra-
chial–ankle etc.) [10–12].
The cardio-ankle vascular index (CAVI) [17,18] assesses
arterial mechanical and elastic properties by means of the
beta stiffness index, which is relatively independent of BP
levels at the time of the measurement. The use of CAVI for
cardiovascular risk assessment was first introduced in Asia
[17–20], and its use has gradually increased in recent years
in Europe [21].
In this report, we present the baseline data of the TRIPLE
A-Stiffness study, which is a multicentre longitudinal study,
performed in a large European population. The analysis of
the baseline data presented herein aimed to establish the
values of arterial stiffness measured simultaneously with
CF-PWV and CAVI in four different age groups of middle-
aged and older adults according to the presence or absence
of MetS.
METHODS
Study design and patients
This is an international multicentre prospective longitudinal
study with three scheduled visits at baseline and after 2 and
5 years of follow-up. In the present report, we present the
analysis of the baseline data.
Patients aged 40 years and older were recruited in 32
outpatient centres participating in the TRIPLE A-Stiffness
study network from 18 countries. All were followed in
outpatient clinics for prevention check-up and/or monitor-
ing of cardiovascular risk factors. To assess the influence of
age on the effects of MetS on arterial stiffness, four age
groups were prespecified: Group 1: 40–49 years, Group 2:
50–59 years, Group 3: 60–74 years and Group 4: at least
75 years.
Noninclusion criteria were factors potentially impairing
the quality of CAVI or PWV measurements or render PWV
recording unreliable, namely: known significant peripheral
arterial disease, ankle–brachial index less than 0.9 (even
unilateral), limb amputation; history of vascular surgery of
the carotid artery, femoral artery or aorta; BMI more than
40 kg/m2; atrial fibrillation and/or other major arrhythmia;
and pregnancy.
Informed written consent was obtained in all included
patients. The study is registered at www.clinicaltrials.gov
with the ID number: NCT02318628.
Investigators collected the data from clinical examina-
tion, BP, PWV and CAVI. Measurements were performed
after 5–10-min rest to obtain a steady haemodynamic state.
At the baseline visit, the following tasks were performed:(1) Blood sample for bioassays or reporting of the
results of the laboratory examination performed at
12 weeks of the visit date.(2) Physical examination, disease history and
treatments.(3) Assessment of MetS components.
(4) Measurement of SBP, DBP and pulse pressure using
a validated automatic electronic device.
(5) ECG.
(6) Measurement of PWV and CAVI as described below.www.jhypertension.com 825
Topouchian et al.Metabolic syndrome assessment
MetS was defined using the National Cholesterol Education
Program – Adult treatment Panel revised version (NCEP-R)
definition [22,23]; all patients were assessed for the pres-
ence of MetS requiring the association of three of the
following five criteria:82(1)6abdominal obesity with waist circumference more
than 102 cm in men and more than 88 cm in women(2) triglycerides at least 150 mg/dl, or presence of a
specific treatment for lipid abnormalities(3) HDL cholesterol less than 40mg/dl in men and less
than 50mg/dl in women, or presence of a specific
treatment for lipid abnormalities(4) SBP at least 130 or DBP at least 85 mmHg, or pres-
ence of antihypertensive treatment(5) fasting glucose at least 100 mg/dl, or presence of
drug treatment for increased glucose.Blood pressure measurements
BP was measured in clinic according to the European Society
of Hypertension guidelines using validated equipment that
meets certification criteria [24]. Two or more readings were
averaged. If the first two readings differed by more than
15mmHg, additional readings were obtained and averaged.
Theaveragevalues of theBPmeasurementswere reported in
the electronic case report form. Ambulatory BP monitoring
(ABPM) was also performed in those patients who agreed.
The ABPM data are currently under analysis.
Pulse wave velocity
Measurements of CF-PWV were performed using a vali-
dated automatic device [Complior (ALAM Medical, Pantin,
France), Sphygmocor (AtCor Medical, Sydney, Australia)
and PulsePen (Diatecne, Milan, Italy)]. Because of the use of
several devices, normalization of the measurement values
was performed according to the European Experts recom-
mendations [12].
Cardio-ankle vascular index
The cardio-ankle vascular index, CAVI, was measured and
automatically calculated using the VaSera system (Fukuda
Denshi Co, Japan) as per the manufacturer’s recommenda-
tions. CAVI requires placement of ECG electrodes on both
wrists, a microphone for phonocardiography on the ster-
num, and four BP cuffs wrapped around the four limbs. The
upper arm and ankle pulse waves, as well as BP are
measured. CAVI is disregarded if the ankle–brachial index
(ABI) is less than 0.9 [17].
Ankle–brachial index
ABI was automatically obtained from the CAVI measure-
ments performed with the VaSera device (Fukuda Denshi
Co). It is calculated bilaterally as the ratio of SBP in the ankle
to the SBP in the arm [17].
Plasma measurements
Glycaemia, total cholesterol, triglycerides, LDL cholesterol,
HDL cholesterol, serum creatinine, creatinine clearancewww.jhypertension.com(modification of diet in renal disease) and haemoglobin
A1c were measured 12 weeks of the study visit.
Statistical analysis
Descriptive values are expressed as mean SD, median
and interquartile range, or number or percentage. For the
comparisons among groups with or without MetS, the
Wilcoxon rank-sum test was used for continuous variables
and the chi-square test for discrete variables. Effects of
each MetS component on sex-adjusted and age-adjusted
CF-PWV and CAVI values were assessed with the Tukey–
Kramer post-hoc test. Interaction between presence of MetS
and age group on CF-PWV or CAVI was assessed with
multivariate trend analysis of variance and Tukey–Kramer
post-hoc test. The same test was used for studying the
interaction between waist circumference component and
age group on CF-PWV or CAVI.
CF-PWV and CAVI variations according to age, sex and
the five components of the MetS were conducted using
multivariate analysis. In the final multivariate model, only
the variables found to be significant at the P less than 0.10
level were retained.
Pearson’s correlation was used to study the relationship
between age and CF-PWV or CAVI and between age-
adjusted and sex-adjusted values of CAVI and CF-PWV.
The Hotelling–Williams test was used for comparison of the
correlation coefficients between age and CF-PWV vs. age
and CAVI.
A P value less than 0.05 was regarded as statistically
significant. Statistical analyses were performed using the
NCSS 9 statistical software package (Kaysville, Utah, USA).RESULTS
General characteristics of the population
A total of 2348 patients were enrolled in 32 centres from 18
countries. A total of 124 patients were excluded from the
present analysis due to either missing information on ele-
ments for the NCEP-2005 MetS classification or lacking
CAVI measurements. Following classification by the
NCEP-R 2005 MetS definition, 1664 patients (74.8%) were
classified with MetS and 560 without.
The main clinical characteristics of the entire population
and the two subgroups according to the presence of MetS
are shown in Table 1. Mean age of this population was
60 11 years (53% women). Patients with MetS were older,
had more often a family history of cardiovascular disease
(CVD) and presented a higher prevalence of cardiovascular
risk factors, stroke, myocardial infarction, angina, heart
failure and renal failure. Patients with MetS had higher
PWV and CAVI values, with this difference being main-
tained after adjustment for age and sex for PWV
(P< 0.0001) but not for CAVI (P¼ 0.40)
Relationship between age and arterial stiffness
Figure 1 shows the effects of age on arterial stiffness
measured with CF-PWV and CAVI in men and women. A
stronger correlation coefficient was observed with CAVI
(r2¼ 0.37; P< 0.0001), y¼ 0.07þ 3.87 than with PWV
(r2¼ 0.14; P< 0.0001), y¼ 0.09þ 4.39. Comparison of theVolume 36  Number 4  April 2018
TABLE 1. Baseline characteristics of the study population
All MetS-no MetS-yes
Number 2224 560 1664
Age (years) 6011 5711 6111
Women (%) 53% 54% 52%
Waist circumference (cm) 10113 9112 10412
Glycaemia (mg/dl) 10834 9319 11436
HDL (mg/dl) 5626 6218 5428
Triglycerides (mg/dl) 14482 10143 15987
SBP (mmHg) 14018 13517 14218
DBP (mmHg) 8511 8311 8511
PP (mmHg) 5514 5213 5614
HR (b/min) 6911 6811 6911
Antidiabetic med. 20% 2% 26%
Hypolipidaemic med. 49% 3% 65%
Antihypertensive med. 75% 45% 85%
Antihypert. drugs (number) 1.681.32 0.771.05 1.991.26
Family history CVD 40% 38% 40%
Obesity 50% 22% 59%
Hypertension 81% 60% 89%
Dyslipidaemia 74% 42% 85%
Diabetes 25% 5% 32%
Stroke 3.5% 2.1% 3.9%
Myocardial infarction 7.6% 2.0% 9.5%
Angina 13% 4% 16%
Heart failure 9.2% 2.9% 11.4%
Renal Failure 5.4% 2.9% 6.3%
CF-PWV (m/s) 9.332.51 8.422.09 9.652.57
CAVI (arbitrary units) 8.321.34 8.061.36 8.411.32
MetS-no, absence of metabolic syndrome; MetS-yes, presence of metabolic syndrome.
Comparison between MetS-no and MetS-yes. CAVI, cardiac-ankle vascular index; CF-
PWV, carotid–femoral pulse wave velocity; CVD, cardiovascular disease; HR, heart rate;
PP, pulse pressure; WC, waist circumference.
P<0.001.
P<0.05.
P<0.01.
Metabolic syndrome and arterial stiffnesscorrelation coefficients using the Hotelling–Williams test
showed that the age/CAVI relationship was statistically
stronger (P< 0.001) than the age/PWV relationship. Effects
of age on arterial stiffness did not differ between men
and women.y = 0.0785x + 4.7835
R² = 0.14; P < 0.0001
y = 0.0945x + 3.5408
R² = 0.15; P < 0.0001
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FIGURE 1 Evolution of pulse wave velocity and cardio-ankle vascular index values with a
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Age-adjusted and sex-adjusted values for CF-PWV but
not CAVI were higher in presence of MetS: for CF-PWV,
values were 9.57 0.06 vs. 8.65 0.10 m/s, (mean SEM;
MetS vs. no MetS; P< 0.001); for CAVI, values were
8.34 0.03 vs. 8.29 0.04 (P¼ 0.40), respectively. The
analysis by sex also showed differential effects of MetS
on CF-PWV and CAVI (Fig. 2). Both measurements of
arterial stiffness were lower in women than in men
although the sex-effect was stronger with CAVI (see below
for multivariate analyses).
Figure 3 shows the effects of MetS on sex-adjusted PWV
and CAVI values in the four predefined age-groups. For
PWV, mean values in patients with vs. without MetS age
group were 8.50 0.15 vs. 7.65 0.19 m/s in the less
than 50 age group, 8.98 0.11 vs. 8.23 0.18 m/s in the
50–59 age group, 10.25 0.10 vs. 9.09 0.20 m/s in the
60–74 age group and 11.23 0.20 vs. 10.06 0.38 m/s in
the at least 75 age group. For CAVI, the same analysis
yielded the following values: 7.24 0.06 vs. 7.02 0.08 in
the less than 50 age group, 7.98 0.05 vs. 7.99 0.08 in the
50–59 age group, 8.85 0.04 vs. 8.86 0.09 in the 60–74
age group and 9.84 0.08 vs. 9.69 0.17 in the at least 75
age group (values are the mean SEM). The interaction
term between age group/MetS on PWV or CAVI was not
statistically significant (P¼ 0.14 for PWV and P¼ 0.38 for
CAVI).
Effects of metabolic syndrome components on
pulse wave velocity and cardio-ankle vascular
index
Figure 4 shows the effects of each of the five MetS compo-
nents on age-adjusted and sex-adjusted PWV and CAVI
values. The presence of any of these five components was
associated with higher PWV values (all P< 0.0001). By
contrast, the effects were much more heterogeneous
with regard to CAVI. Glycaemia and BP components werey = 0.0762x + 3.9197
R² = 0.38; P < 0.0001
y = 0.0757x + 3.6557
R² = 0.38; P < 0.0001
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FIGURE 2 Effects of metabolic syndrome and sex-adjusted on age-adjusted pulse wave velocity and cardio-ankle vascular index values.
Topouchian et al.associated with higher CAVI values (P< 0.0001 and <0.02,
respectively) whereas the HDL or triglyceride component
did not influence CAVI. Finally, presence of high waist
circumference was associated with lower age-adjusted and
sex-adjusted CAVI values.
As there are several interactions between the different
MetS components, the arterial effects of the five MetS
components were also tested using a multiple regression
analysis including age and sex. The results of this
analysis are shown in Table 2. Older age and presence
of the BP, glycaemia and HDL components were indepen-
dent determinants of high CF-PWV. Sex and the two
remaining components of the MetS (waist circum-
ference and triglycerides) did not show an independent
effect on PWV. On the other hand, older age, male sex,
presence of the BP and glycaemia components and
absence of the overweight component (i.e. lower waist**
**
***
(0.10)
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FIGURE 3 Effects of metabolic syndrome on sex-adjusted pulse wave velocity and cardio
828 www.jhypertension.comcircumference) were all independent determinants of
higher CAVI values.
The interaction between each of the five MetS compo-
nents was subsequently tested within the four age groups
on the effects on PWV and CAVI. The only significant age/
MetS component interaction regarded the effects of waist
circumference on CAVI (P¼ 0.04). To further investigate
this interaction, the effects of waist circumference on CAVI
were analysed according to both sex and age groups
(Fig. 5). The age/waist circumference interaction on CAVI
was found to be strong in women with lower CAVI values in
the presence of high waist circumference in the older group
of patients.
All of the aforementioned differences in the determina-
tion of CAVI and PWV led as expected to a low correlation
between the age-adjusted and sex-adjusted values of these
variables (Fig. 6).6
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-ankle vascular index values according to age groups.
Volume 36  Number 4  April 2018
8.0
8.5
9.0
9.5
10.0
No Yes
Ag
e 
an
d 
se
x 
ad
ju
st
ed
 P
W
V 
(m
/s
)
WC
7.5
8.0
8.5
No Yes
Ag
e 
an
d 
se
x 
ad
ju
st
ed
 C
AV
I
WC
8.0
8.5
9.0
9.5
10.0
No Yes
Ag
e 
an
d 
se
x 
ad
ju
st
ed
 P
W
V 
(m
/s
)
TG
7.5
8.0
8.5
No Yes
Ag
e 
an
d 
se
x 
ad
ju
st
ed
 C
AV
I
TG
8.0
8.5
9.0
9.5
10.0
No Yes
Ag
e 
an
d 
se
x 
ad
ju
st
ed
 P
W
V 
(m
/s
)
HDL
7.5
8.0
8.5
No Yes
Ag
e 
an
d 
se
x 
ad
ju
st
ed
 C
AV
I
HDL 
8.0
8.5
9.0
9.5
10.0
No Yes
Ag
e 
an
d 
se
x 
ad
ju
st
ed
 P
W
V 
(m
/s
)
BP
7.5
8.0
8.5
No Yes
Ag
e 
an
d 
se
x 
ad
ju
st
ed
 C
AV
I
BP 
8.0
8.5
9.0
9.5
10.0
No Yes
Ag
e 
an
d 
se
x 
ad
ju
st
ed
 P
W
V 
(m
/s
)
Glu
7.5
8.0
8.5
No Yes
Ag
e 
an
d 
se
x 
ad
ju
st
ed
 C
AV
I
Glu
P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
P = 0.002 P = 0.14 P = 0.31 P = 0.02 P < 0.0001
(a)
(b)
FIGURE 4 Effects of each metabolic syndrome component on sex-adjusted and age-adjusted pulse wave velocity (a) and cardio-ankle vascular index (b) values.
Metabolic syndrome and arterial stiffnessDISCUSSION
This large European multicenter study reports the values of
arterial stiffness measured simultaneously with two different
methods, namely CF-PWV and CAVI, in four different age
groups of patients aged 40 and older with or without MetS.TABLE 2. Multivariate analysis in explaining pulsewave velocity and ca
of the five metabolic syndrome components
PWV R2 (%)
Age (years) 11.2
Women 0.2
BP (yes) 1.0
Glu (yes) 1.4
HDL (yes) 0.7
WC (yes) –
TG (yes) –
Model 13.7
CAVI R2 (%)
Age (years) 35.6
Women 1.2
BP (yes) 0.2
Glu (yes) 1.2
WC (yes) 1.1
TG (yes) –
HDL (yes) –
Model 36.6
Yes means presence of this MetS component. BP, blood pressure; Glu, glucose; MetS, metaboli
Journal of HypertensionMeasuring arterial stiffness with
carotid–femoral pulse wave velocity and
cardio-ankle vascular index
Although CF-PWV and CAVI both represent measurements
of arterial stiffness, their fundamental principles differ, for
mainly two reasons:rdio-ankle vascular index variations according to age, sex and each
Reg CoeffSEM
0.0760.005 <0.0001
0.190.11 0.09
0.810.19 <0.0001
0.570.11 <0.0001
0.420.12 0.0003
– 0.22
– 0.29
Reg CoeffSEM
0.0740.002 <0.0001
0.240.05 <0.0001
0.180.08 0.03
0.250.05 <0.0001
0.250.05 <0.0001
– 0.29
– 0.49
c syndrome; Reg Coeff, regression coefficient; TG, triglycerides; WC, waist circumference.
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FIGURE 5 Effects of the waist circumference on cardio-ankle vascular index values according to sex and age groups.
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0PWV is based on the Moens–Korteweg/Bramwell–
Hill Eqs. [25] and measures the velocity of the pulse
waves between two arterial sites. It is well known
that this velocity is dependent on both arterial struc-
ture/function but also on distension pressure at the
time of the measurement [26–28], thereby explain-
ing a more pronounced influence of BP variations
during PWV assessment. On the other hand, CAVI
corresponds to the b index, which reflects the slope
of the relationship between changes in pressure and
changes in volume [17–20], thus explaining why this
index is much less dependent on acute pressure
variations at the time of the measurements. The
present results showing a less pronounced effect
of BP levels on CAVI than on CF-PWV goes along
previous observations on the same topic [18,21,29].
Recently, Spronck et al. [30] concluded that CAVI as
it is currently implemented differs from the b0
stiffness index and is inherently BP-dependent, thus
potentially leading to erroneous conclusions in arte-
rial stiffness; these conclusions have been debated
in a recent reply by Shirai et al. [31] who showed that
the two arterial mathematical methods (CAVI andy = 0.1141x + 7.27
R² = 0.0632; P < 0.0001
0
5
0
5
0 5 10 15 20 25
PWV age and sex adjusted (m/s)
Relationship between age-adjusted and sex-adjusted pulse wave velocity
cardio-ankle vascular index values.
www.jhypertension.comb0) were not different and concluded that the influ-
ence of BP levels on CAVI was very weak.
The results of the current study confirm the relative
‘pressure-independency’ of the CAVI. It is however
important to clarify that both CF-PWV and CAVI
are influenced by the prevalence of hypertension,
as chronic hypertension modifies the arterial struc-
ture and function increasing arterial stiffness. There-
fore, the relative BP-independence of CAVI as
compared with CF-PWV refers to the BP at the time
of measurement but not the chronic BP levels
over time.(2) CF-PWV measures arterial stiffness primarily of the
descending aorta, whereas CAVI estimates stiffness
of a more general territory including ascending
aorta, aortic arch, descending aorta and lower limb
arteries [32].These two differences may explain why the correla-
tion between CF-PWV and CAVI, although statistically
significant, showed a weak regression coefficient
(r2¼ 0.18). Our results corroborate those of previous stud-
ies [21] performed in smaller number of patients and
reporting low correlation coefficients between CF-PWV
and CAVI.
Effects of age and sex on cardio-ankle vascular
index and carotid–femoral pulse wave velocity
Several studies have established that age is associated with
arterial stiffness in normal patients and patients with various
conditions for both CF-PWV and CAVI. Moreover, several
experts suggested considering normal values of arterial
stiffness according to age [12]. The results of our study
showed in this specific population that both CF-PWV and
CAVI were correlated with age although with a stronger
correlation coefficient with CAVI (r2¼ 0.37) than with CF-
PWV (r2¼ 0.14). Furthermore, in the current study, effects
of sex (higher arterial stiffness in men than in women) were
detected with CAVI but not with CF-PWV. The fact that
CAVI explores a larger vascular territory as stated above
could explain such differences between the two methods.Volume 36  Number 4  April 2018
Metabolic syndrome and arterial stiffnessEffects of metabolic syndrome on cardio-ankle
vascular index and carotid–femoral pulse wave
velocity
Our results indicate differential effects according to the
different MetS components as well as according to the
different methods for evaluating vascular stiffness, with
important implications for risk stratification of patients with
and without MetS.
Previous studies have shown that MetS is associated with
increased cardiovascular organ damage and acceleration of
age-related arterial changes such as arterial stiffness mainly
assessed with PWV [6,7]. The current study corroborates
these previous reports and show that patients with MetS
exhibited significantly higher CF-PWV in all age groups. In
contrast, CAVI was not altered in the presence of MetS,
thereby further reinforcing that these two methods reflect
different aspects of arterial stiffness. In the current study,
certain MetS components were found to have different, even
opposite, effects on CF-PWV and CAVI. Thus, whereas all
five MetS components were positively associated with age-
adjusted and sex-adjusted CF-PWV, only high glycaemia and
high BP components exhibited a positive association with
CAVI. Significantly, the lipidaemia criteria (lowHDLandhigh
triglyceride components) were not associated with CAVI,
and even more unexpectedly, high waist circumference was
associated with lower CAVI values. The multivariate analysis
confirmed these differences in the effects of MetS compo-
nents, with high-BP and high-glycaemia as the common
independent predictor for increased PWV and CAVI.
The explanation for the discordant effects of waist cir-
cumference on CF-PWV and CAVI remains to be estab-
lished. Although previous studies have suggested that
overweight/obesity is not associated with increased CAVI
[33], this is the first report to raise the notion of opposite
effects of waist circumference on CF-PWV and CAVI. It
should however be acknowledged that we cannot exclude
that abdominal obesity may lead to an over-estimation of
the distance in the CF-PWV formula, leading to an overes-
timation of the impact of waist circumference on arterial
stiffness by CF-PWV [12]. However, the different centres
participating in the study used the appropriate method for
distance measurements to avoid this caveat.
The role of overweight and waist circumference in MetS
remains a matter of debate. In the International Diabetes
Federation definition, the presence of central obesity is an
obligatory criterion for the presence of MetS [34], although
this is not the case for most other guidelines and consensus
articles [22,23]. Moreover, the waist circumference thresh-
olds differ according to the various classifications and
different ethnic origins [23]. Although the present analysis
was not designed to answer this question, the ongoing
longitudinal component of the current study should pro-
vide answers to these questions by assessing the long-term
evolution of CAVI and CF-PWV values but also by recording
the cardiovascular events in this population.Interest of cardio-ankle vascular index for the
evaluation of arterial stiffness
In Europe, CF-PWV is used in several specialized centres
and recommended by scientific societies as the goldJournal of Hypertensionstandard to assess arterial stiffness [9–12]. The results of
this study show that CAVI provides complementary infor-
mation to that provided by PWV. Clinical studies now show
that CAVI could represent a useful tool for the assessment of
arterial health in large multicenter studies, owing to several
advantages related to feasibility, reproducibility and facility
of use, with little or no observer bias [17,21,35].
Beyond these practical aspects, the interest of CAVI is
also related to the minimal impact of BP values at the time of
the measurements, which allows a better assessment of the
intrinsic elastic properties of the vascular system. This
may be of major interest in some subgroups of patients
especially in very old patients in whom BP levels are
very often influenced by comorbidities and poor general
condition [36].
Limitations of the study: Some parameters of clinical
interest were not taken into account in the current study,
namely: the cohorts included patients both with and with-
out prevalent CVD; cardiac function was unknown and
pharmacological treatments were not taken into consider-
ation. No specific sampling of C reactive protein or other
vascular biomarkers was performed. However, this also
implies a generalizability of the results to unselected
patient populations.
In conclusion, the current large European multicentre
study shows the differential impact of MetS and age on
CAVI and CF-PWV. Age had a more pronounced effect on
CAVI, whereas MetS increased CF-PWV but not CAVI. This
important finding is probably due to the heterogeneous
effects of the MetS components on CAVI. The clinical
significance of these original results will be assessed during
the longitudinal phase of the study.
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Metabolic syndrome and arterial stiffnessReviewer’s Summary EvaluationReviewer 2
This study assesses the association of stiffness indices
measured as carotid-femoral pulse wave velocity (cfPWV,
pressure dependent) and cardio-ankle vascular index
(CAVI, relatively pressure independent) with meta-
bolic syndrome (Mets). Baseline results highlight the
difference in sensitivity of cfPWV and CAVI to age
and blood pressure as well as to components of Mets.Journal of HypertensionA future follow up study in the same cohort aims to
confirm whether CAVI gives additional prognostic infor-
mation in relation to intrinsic vascular aging in Mets,
which is not obtained by cfPWV. The effect of correcting
CAVI for a potential theoretical pressure dependency
due to the variation in the ’reference’ pressure, as required
in the computation of CAVI, has not been explicitly
assessed.www.jhypertension.com 833
